Loading…
Reported covered position: Chief of Staff, Rep. Marc Veasey (2017-2021); Deputy Staff Director, Ways and Means Committee (2007-2014); Deputy Staff Director, House Rules Committee (2001-2007); Legislative Director, Rep. Martin Frost (2000-2001)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug diagnosis and screening reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2026 · third_quarter · Q3
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; clinical trial reforms; FDA policy issues
Source: Senate LDA
Intellectual property; 340B Program; Medicare & Medicaid prescription drug diagnosis and screening reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug diagnosis and screening reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; clinical trial reforms; FDA policy issues
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Implementation and extension of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping; One Big Beautiful Bill Act (HR.1)
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Implementation and extension of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping; One Big Beautiful Bill Act (HR.1)
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Implementation and extension of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping; One Big Beautiful Bill Act (HR.1)
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Implementation and extension of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping; One Big Beautiful Bill Act (HR.1)
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Implementation and extension of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping; One Big Beautiful Bill Act (HR.1)
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
Impacts and Outcomes for Health Career Training Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Share the Savings with Seniors Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Improve and Enhance the Work Opportunity Tax Credit Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Improve and Enhance the Work Opportunity Tax Credit Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Improve and Enhance the Work Opportunity Tax Credit Act
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
American Rescue Plan Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement, coverage and value; "Developing an Innovative Strategy for Antimicrobial Resistant Microorganism Act of 2019 (DISARM Act)"; American Rescue Plan Act, 2021" (HR.1319); "Build Back Better" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); CMS National Coverage Determination on Alzheimer's disease
American Rescue Plan Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement, coverage and value; "Developing an Innovative Strategy for Antimicrobial Resistant Microorganism Act of 2019 (DISARM Act)"; American Rescue Plan Act, 2021" (HR.1319); "Build Back Better" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
American Rescue Plan Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement, coverage and value; "Developing an Innovative Strategy for Antimicrobial Resistant Microorganism Act of 2019 (DISARM Act)"; American Rescue Plan Act, 2021" (HR.1319); "Inflation Reduction Act" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
Client: ELI LILLY AND COMPANY · Firm: ELI LILLY AND COMPANY
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Patient protection; Drug supply chain and shortages; Drug pricing, value and access; Transparency; Intellectual property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act 2021" (S 2076 & HR.3932); "Inflation Reduction Act" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); Prescription Drug User Fee reauthorization; prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act 2021" (S 2076 & HR.3932); "Inflation Reduction Act" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); Prescription Drug User Fee reauthorization; prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Patient protection; Drug supply chain and shortages; Drug pricing, value and access; Transparency; Intellectual property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act 2021" (S 2076 & HR.3932); "Build Back Better" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); Prescription Drug User Fee reauthorization; prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833)
Patient protection; Drug supply chain and shortages; Drug pricing, value and access; Transparency; Intellectual property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act 2021" (S 2076 & HR.3932); "Build Back Better" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); Prescription Drug User Fee reauthorization; prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act 2021" (S 2076 & HR.3932); "Inflation Reduction Act" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); Prescription Drug User Fee reauthorization; prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Patient protection; Drug supply chain and shortages; Drug pricing, value and access; Transparency; Intellectual property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act 2021" (S 2076 & HR.3932); "Build Back Better" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); Prescription Drug User Fee reauthorization; prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833)
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement, coverage and value; "Developing an Innovative Strategy for Antimicrobial Resistant Microorganism Act of 2019 (DISARM Act)"; "Inflation Reduction Act" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Implementation of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Puerto Rico tax issues; "Build Back Better" (HR.5376); expensing of research and development costs
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Pharmaceutical intellectual property issues
Implementation and extension of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping
Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act; clinical trial reforms; FDA policy issues
Intellectual property; 340B Program; Medicare & Medicaid prescription drug diagnosis and screening reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2026 · second_quarter · Q2
Implementation and extension of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Intellectual property; 340B Program; Medicare & Medicaid prescription drug diagnosis and screening reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care
Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act
Pharmaceutical intellectual property issues
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2026 · first_quarter · Q1
Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care
Pharmaceutical intellectual property issues
Implementation and extension of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping
Intellectual property; 340B Program; Medicare & Medicaid prescription drug diagnosis and screening reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2025 · fourth_quarter · Q4
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Pharmaceutical intellectual property issues
Implementation and extension of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping; One Big Beautiful Bill Act (HR.1)
Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2025 · second_quarter · 2A
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Pharmaceutical intellectual property issues
Implementation and extension of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping; One Big Beautiful Bill Act (HR.1)
Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2025 · first_quarter · 1A
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2025 · third_quarter · Q3
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2025 · second_quarter · 2A
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2025 · first_quarter · 1A
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2025 · second_quarter · Q2
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care; One Big Beautiful Bill Act (HR.1)
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2025 · first_quarter · Q1
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Policy matters related to Artificial Intelligence in health care
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2024 · fourth_quarter · 4A
Pharmaceutical intellectual property issues
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2024 · fourth_quarter · 4A
Pharmaceutical intellectual property issues
Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2024 · fourth_quarter · 4A
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2024 · fourth_quarter · Q4
Pharmaceutical intellectual property issues
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2024 · third_quarter · Q3
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2024 · second_quarter · Q2
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Hospital discounts; 340B program
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2024 · first_quarter · Q1
Pharmaceutical intellectual property issues
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2023 · fourth_quarter · Q4
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Pharmaceutical intellectual property issues
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2023 · third_quarter · Q3
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
Implementation of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2023 · second_quarter · 2A
Hospital discounts; 340B program
Pharmaceutical intellectual property issues
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2023 · second_quarter · Q2
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2023 · first_quarter · Q1
Pharmaceutical intellectual property issues
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2022 · fourth_quarter · Q4
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement, coverage and value; "Developing an Innovative Strategy for Antimicrobial Resistant Microorganism Act of 2019 (DISARM Act)"; "Inflation Reduction Act" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2022 · third_quarter · Q3
Implementation of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Puerto Rico tax issues; "Inflation Reduction Act" (HR.5376); expensing of research and development costs
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Hospital discounts; 340B program; Affordable Prescriptions for Patients Act of 2021 (S.1435)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2022 · second_quarter · Q2
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement, coverage and value; "Developing an Innovative Strategy for Antimicrobial Resistant Microorganism Act of 2019 (DISARM Act)"; American Rescue Plan Act, 2021" (HR.1319); "Build Back Better" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2022 · first_quarter · Q1
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Implementation of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Puerto Rico tax issues; "Build Back Better" (HR.5376); expensing of research and development costs
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2021 · fourth_quarter · Q4
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement, coverage and value; "Developing an Innovative Strategy for Antimicrobial Resistant Microorganism Act of 2019 (DISARM Act)"; American Rescue Plan Act, 2021" (HR.1319); "Build Back Better" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2021 · third_quarter · Q3
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873)
Pharmaceutical intellectual property issues
Hospital discounts; 340B program
ELI LILLY AND COMPANY via ELI LILLY AND COMPANY
2021 · second_quarter · Q2
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement, coverage and value; Developing an Innovative Strategy for Antimicrobial Resistant Microorganism Act of 2019 (DISARM Act); American Rescue Plan Act, 2021 (HR.1319)
Pharmaceutical intellectual property issues
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Pharmaceutical intellectual property issues
Implementation and extension of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping
Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage, value and access; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Pharmaceutical intellectual property issues
Implementation and extension of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping; One Big Beautiful Bill Act (HR.1)
Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement pricing, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; One Big Beautiful Bill Act (HR.1)
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Pharmaceutical intellectual property issues
Implementation and extension of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping; One Big Beautiful Bill Act (HR.1)
Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Pharmaceutical intellectual property issues
Implementation and extension of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping
Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Pharmaceutical intellectual property issues
Implementation and extension of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping; One Big Beautiful Bill Act (HR.1)
Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil; US Tariffs
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Pharmaceutical intellectual property issues
Implementation and extension of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping
Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Implementation of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Implementation of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value, access and quality; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Pharmaceutical intellectual property issues
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Implementation of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping
Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Implementation of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping
Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Hospital discounts; 340B program; Prescription drug value, access, quality and compliance with Drug Quality and Safety Act
Implementation of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues; round-tripping
Pharmaceutical intellectual property issues
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value, access and quality
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Pharmaceutical intellectual property issues
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
Implementation of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues
Patient protection; Pharmaceutical supply chain issues and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act; Policy matters related to Artificial Intelligence in health care.
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Hospital discounts; 340B program
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Implementation of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.954/HR.1488), The INSULIN Act
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Implementation of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax; Pension and retirement benefit issues
Hospital discounts; 340B program
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Pharmaceutical intellectual property issues
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Hospital discounts; 340B program
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Implementation of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Hospital discounts; 340B program
Implementation of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax
Pharmaceutical intellectual property issues
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Intellectual property; 340B Program; Medicare & Medicaid prescription drug reimbursement, coverage and value; Implementation of the "Inflation Reduction Act" (HR.5376); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Hospital discounts; 340B program
Implementation of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Expensing of research and development costs; Global minimum tax
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; Implementation of the "Inflation Reduction Act" (HR.5376); Prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-India, and US-Brazil
Pharmaceutical intellectual property issues
Implementation of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Puerto Rico tax issues; "Inflation Reduction Act" (HR.5376); expensing of research and development costs
Patient protection; Drug supply chain and shortages; Drug pricing, coverage, value and access; Transparency; Intellectual property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act 2021" (S 2076 & HR.3932); "Inflation Reduction Act" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); Prescription Drug User Fee reauthorization; prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Hospital discounts; 340B program; Affordable Prescriptions for Patients Act of 2021 (S.1435)
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Pharmaceutical intellectual property issues
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Patient protection; Drug supply chain and shortages; Drug pricing, value and access; Transparency; Intellectual property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act 2021" (S 2076 & HR.3932); "Inflation Reduction Act" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); Prescription Drug User Fee reauthorization; prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement, coverage and value; "Developing an Innovative Strategy for Antimicrobial Resistant Microorganism Act of 2019 (DISARM Act)"; American Rescue Plan Act, 2021" (HR.1319); "Inflation Reduction Act" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); CMS National Coverage Determination on Alzheimer's disease; The INSULIN Act
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Implementation of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Puerto Rico tax issues; "Build Back Better" (HR.5376); expensing of research and development costs
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Pharmaceutical intellectual property issues
Hospital discounts; 340B program; Affordable Prescriptions for Patients Act of 2021 (S.1435)
Patient protection; Drug supply chain and shortages; Drug pricing, value and access; Transparency; Intellectual property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act 2021" (S 2076 & HR.3932); "Build Back Better" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); Prescription Drug User Fee reauthorization; prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833), The INSULIN Act
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Patient protection; Drug supply chain and shortages; Drug pricing, value and access; Transparency; Intellectual property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act 2021" (S 2076 & HR.3932); "Build Back Better" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); Prescription Drug User Fee reauthorization; prescription drug approval; Affordable Insulin Now Act (S.3700/HR.6833)
Pharmaceutical intellectual property issues
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement, coverage and value; "Developing an Innovative Strategy for Antimicrobial Resistant Microorganism Act of 2019 (DISARM Act)"; American Rescue Plan Act, 2021" (HR.1319); "Build Back Better" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435); CMS National Coverage Determination on Alzheimer's disease
Hospital discounts; 340B program; Affordable Prescriptions for Patients Act of 2021 (S.1435)
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Implementation of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Puerto Rico tax issues; "Build Back Better" (HR.5376)
Multi-lateral threats to IP and the biopharmaceutical industry; Drug importation; Prescription drug value and access; "Affordable Prescriptions for Patients Act of 2021 (S 1435 & HR.2873); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Hospital discounts; 340B program; Affordable Prescriptions for Patients Act of 2021 (S.1435)
Patient protection; Drug supply chain and shortages; Drug pricing, value and access; Transparency; Intellectual property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act 2021" (S 2076 & HR.3932); "Build Back Better" (HR.5376); Affordable Prescriptions for Patients Act of 2021 (S.1435)
Pharmaceutical intellectual property issues
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Patient protection; Drug supply chain and shortages; Drug pricing, value and access; Transparency; Intellectual property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act 2021" (S 2076 & HR.3932); "Build Back Better" (HR.5376)
Intellectual property; 340B Program; PPACA; Medicare & Medicaid prescription drug reimbursement, coverage and value; "Developing an Innovative Strategy for Antimicrobial Resistant Microorganism Act of 2019 (DISARM Act)"; American Rescue Plan Act, 2021" (HR.1319); "Build Back Better" (HR.5376)
Implementation of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Puerto Rico tax issues; "Build Back Better" (HR.5376)
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-Kenta, and US-Brazil
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Patient protection; Drug supply chain and shortages; Drug pricing, value and access; Transparency; Intellectual property; Health insurance accessibility; "Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act"; American Rescue Plan Act, 2021 (HR.1319)
Issues related to intellectual property protection and market access within current trade negotiations. Canada IP; USMCA implementation; Saudi Arabia; Mexico patent linkage; Special 301; Trade talks: US-Japan, US-China, US-EU, US-UK, US-Kenta, and US-Brazil
Implementation of the Tax Cuts and Jobs Act; Domestic manufacturing tax incentives; Puerto Rico tax issues; Pension and retirement benefit issues
Hospital discounts; 340B program
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)